Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin.
The effects of heme, when added as the ferric chloride salt, hemin, on human erythroid cells grown in a two-phase liquid culture system were studied. When added together with erythropoietin, on initiation of the second phase of the culture, hemin greatly accelerated hemoglobin (Hb) accumulation in these cells. The effect was greater during their early stages of maturation, suggesting that heme availability is then a rate-limiting step for Hb synthesis. Hemin increased preferentially the production of fetal Hb (HbF) compared with adult Hb; this was associated with a selective twofold elevation in gamma-mRNA levels. Using succinylacetone, a potent inhibitor of heme synthesis, we showed that exogenously supplied hemin could be incorporated into the de novo formed Hb. Therefore, the mechanism of hemin action may be several fold, including effects on globin gene transcription and posttranslational events, eg, supplying the prosthetic group for Hb assembly. Hemin increased HbF of cells derived from patients with sickle cell anemia and beta-thalassemia as well as that of cells from normal donors. Moreover, when added in combination with other HbF-augmenting agents such as the cytotoxic drug, hydroxyurea, a synergistic effect was obtained, with considerably less cytotoxicity than with hydroxyurea alone. These results have clinical potential in light of the ameliorating effect that increased HbF has in patients with genetic diseases of the beta-globin chain and raise the possibility of combined treatment with hemin and other drugs now being used to treat these diseases.
Fibach
E
E
Department of Hematology, Hadassah University Hospital, Jerusalem, Israel.
Kollia
P
P
Schechter
A N
AN
Noguchi
C T
CT
Rodgers
G P
GP
D000755:Anemia, Sickle Cell / Q000097:blood; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004357:Drug Synergism; D015672:Erythroid Precursor Cells / Q000378:metabolism*; D005319:Fetal Hemoglobin / Q000096:biosynthesis*; D015870:Gene Expression; D005914:Globins / Q000235:genetics; D006427:Hemin / Q000494:pharmacology*; D006454:Hemoglobins / Q000096:biosynthesis*; D006537:Heptanoates / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D066298:In Vitro Techniques; D012333:RNA, Messenger / Q000235:genetics; D013997:Time Factors; D017086:beta-Thalassemia / Q000097:blood
D006454:Hemoglobins; D006537:Heptanoates; D012333:RNA, Messenger; C020804:succinylacetone; D006427:Hemin; D005914:Globins; D005319:Fetal Hemoglobin; D006918:Hydroxyurea